Indaptus Therapeutics, Inc.
INDPFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Indaptus Therapeutics, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Mar 24, 2026. The latest institutional report shown is dated Mar 31, 2025; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | 2025-03-31 | 98 | Not shown | SEC filing |
| Tower Research Capital LLC (TRC) | 2025-03-31 | 3,493 | Not shown | SEC filing |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 2025-03-31 | 0 | $0 | SEC filing |
| JPMORGAN CHASE & CO | 2025-03-31 | 17 | Not shown | SEC filing |
| Vivaldi Capital Management LP | 2025-03-31 | 24,000 | Not shown | SEC filing |
| INVESTMENT HOUSE LLC | 2025-03-31 | 128,851 | Not shown | SEC filing |
| GROUP ONE TRADING LLC | 2025-03-31 | 7 | Not shown | SEC filing |
| STRATEGY ASSET MANAGERS LLC | 2025-03-31 | 45,336 | Not shown | SEC filing |
| RENAISSANCE TECHNOLOGIES LLC | 2025-03-31 | 28,500 | Not shown | SEC filing |
| VANGUARD GROUP INC | 2025-03-31 | 256,265 | Not shown | SEC filing |
| MORGAN STANLEY | 2025-03-31 | 884 | Not shown | SEC filing |
| DANSKE BANK A/S | 2025-03-31 | 1 | Not shown | SEC filing |
| Bangor Savings Bank | 2025-03-31 | 350 | Not shown | SEC filing |
| SBI Securities Co., Ltd. | 2025-03-31 | 4,400 | Not shown | SEC filing |
| GEODE CAPITAL MANAGEMENT, LLC | 2025-03-31 | 124,967 | Not shown | SEC filing |
| Pine Valley Investments Ltd Liability Co | 2025-03-31 | 43,771 | Not shown | SEC filing |
| STATE STREET CORP | 2025-03-31 | 13,073 | Not shown | SEC filing |
| Virtu Financial LLC | 2025-03-31 | 12,872 | Not shown | SEC filing |
| WELLS FARGO & COMPANY/MN | 2025-03-31 | 64 | Not shown | SEC filing |
| UBS Group AG | 2025-03-31 | 87 | Not shown | SEC filing |
- Each value is checked against Indaptus Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 19 rows: no share price from within three months of their report dates is on file, so they could not be checked.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- UBS Group AG: 2,523 shares reported 2024-12-31; 87 shares reported 2025-03-31.
- WELLS FARGO & COMPANY/MN: 64 shares reported 2024-12-31; 64 shares reported 2025-03-31.
- STATE STREET CORP: 13,073 shares reported 2024-12-31; 13,073 shares reported 2025-03-31.
- Pine Valley Investments Ltd Liability Co: 43,921 shares reported 2024-12-31; 43,771 shares reported 2025-03-31.
- GEODE CAPITAL MANAGEMENT, LLC: 82,118 shares reported 2024-12-31; 124,967 shares reported 2025-03-31.
- SBI Securities Co., Ltd.: 3,900 shares reported 2024-12-31; 4,400 shares reported 2025-03-31.
- Bangor Savings Bank: 400 shares reported 2024-12-31; 350 shares reported 2025-03-31.
- DANSKE BANK A/S: 1 share reported 2024-12-31; 1 share reported 2025-03-31.
- VANGUARD GROUP INC: 256,265 shares reported 2024-12-31; 256,265 shares reported 2025-03-31.
- RENAISSANCE TECHNOLOGIES LLC: 27,700 shares reported 2024-12-31; 28,500 shares reported 2025-03-31.
- STRATEGY ASSET MANAGERS LLC: 45,336 shares reported 2024-12-31; 45,336 shares reported 2025-03-31.
- INVESTMENT HOUSE LLC: 100,176 shares reported 2024-12-31; 128,851 shares reported 2025-03-31.
Showing the 12 most recent filer reports.
7 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Indaptus Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2023-08-10 · Anderson Glen R.: Larger than all 8 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-03-23 | Lazar David E. · Director | Series AA Convertible Non-Redeemable Preferred Stock | S — Open market or private sale | −196,800 | unknown | SEC filing |
| 2026-03-23 | Lazar David E. · Director | Series AAA Convertible Non-Redeemable Preferred Stock | S — Open market or private sale | −700,000 | unknown | SEC filing |
| 2023-08-14 | Anderson Glen R. · 10% owner | Common Stock | P — Open market or private purchase | +23,934 | 2.34 | SEC filing |
| 2023-08-11 | Anderson Glen R. · 10% owner | Common Stock | P — Open market or private purchase | +35,064 | 2.12 | SEC filing |
| 2023-08-10 | Anderson Glen R. · 10% owner | Common Stock | P — Open market or private purchase | +44,354 | 1.94 | SEC filing |
| 2022-12-01 | Litchev Boyan Vesselinov · Chief Medical Officer | Common Stock | P — Open market or private purchase | +500 | 1.87 | SEC filing |
| 2022-11-22 | Litchev Boyan Vesselinov · Chief Medical Officer | Common Stock | P — Open market or private purchase | +500 | 1.83 | SEC filing |
| 2022-11-21 | Meckler Jeffrey A · CEO and Director | Common stock | P — Open market or private purchase | +9,600 | 1.90 | SEC filing |
Showing 8 of 14 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-02-26 | Jabbour Jerome D · Director | Option to Buy Common Stock | A — Grant, award, or other acquisition | +25,000 | SEC filing |
| 2026-02-11 | Meckler Jeffrey A · Co-Chief Executive Officer | Warrants (right to buy) | A — Grant, award, or other acquisition | +1,519 | SEC filing |
| 2026-02-11 | Meckler Jeffrey A · Co-Chief Executive Officer | Warrants (right to buy) | A — Grant, award, or other acquisition | +3,033 | SEC filing |
| 2026-02-11 | Meckler Jeffrey A · Co-Chief Executive Officer | Warrants (right to buy) | A — Grant, award, or other acquisition | +12,136 | SEC filing |
| 2026-01-20 | Ben-Tzvi Avraham · Director | Common Stock | A — Grant, award, or other acquisition | +25,000 | SEC filing |
| 2026-01-07 | NATAN DAVID · Director | Option to Buy Common Stock | A — Grant, award, or other acquisition | +25,000 | SEC filing |
| 2025-12-23 | Ben-Tzvi Avraham · Director | Option to Buy Common Stock | A — Grant, award, or other acquisition | +25,000 | SEC filing |
| 2025-12-22 | Meckler Jeffrey A · Co-Chief Executive Officer | Common Stock | A — Grant, award, or other acquisition | +216,617 | SEC filing |
Showing 8 of 10 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-02-11 | Meckler Jeffrey A · Co-Chief Executive Officer | Warrants (right to buy) | D — Disposition to the issuer | −12,136 | SEC filing |
| 2026-02-11 | Meckler Jeffrey A · Co-Chief Executive Officer | Warrants (right to buy) | D — Disposition to the issuer | −1,519 | SEC filing |
| 2026-02-11 | Meckler Jeffrey A · Co-Chief Executive Officer | Warrants (right to buy) | D — Disposition to the issuer | −3,033 | SEC filing |
| 2025-04-10 | MADDALUNA ANTHONY J · Director | Stock Option (right to buy) | D — Disposition to the issuer | −250 | SEC filing |
| 2025-04-10 | Linscott Walt Addison · Chief Operating Officer | Stock Option (right to buy) | D — Disposition to the issuer | −750 | SEC filing |
| 2025-04-10 | Meckler Jeffrey A · Chief Executive Officer | Stock Option (right to buy) | D — Disposition to the issuer | −813 | SEC filing |
| 2025-04-10 | Pomerantz Roger · Director | Stock Option (right to buy) | D — Disposition to the issuer | −250 | SEC filing |
| 2025-04-10 | Hayes William B · Director | Stock Option (right to buy) | D — Disposition to the issuer | −500 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.